News & Events
-
March 20, 2017
Critical Path Institute Launches Type 1 Diabetes Consortium
March 20, 2017 Critical Path Institute Launches Type 1 Diabetes Consortium Tucson, Ariz., March 20, 2017 –Critical Path Institute (C-Path) is pleased to announce the launch of the Type 1 Diabetes (T1D) Consortium. Funded by The Leona M. and Harry B. Helmsley Charitable Trust; Janssen Research & Development, LLC; JDRF International; and Sanofi, the T1D...... -
January 17, 2017
ReSeqTB Data Platform Now Available to Public
January 17, 2017 TUCSON, Ariz., January 17, 2017 —The Rapid Drug Susceptibility Testing Consortium, coordinated by the Critical Path Institute through the Critical Path to TB Drug Regimens (CPTR) initiative, announces the public launch of the Relational Sequencing TB Data Platform (ReSeqTB). ReSeqTB is a data-sharing platform and analytic visualization tool that can...... -
November 2, 2016
CDISC, C-Path, and TransCelerate Announce Therapeutic Area Standard for Kidney Transplant
November 2, 2016 CDISC, C-Path, and TransCelerate Announce Therapeutic Area Standard for Kidney Transplant TUCSON, Ariz., and AUSTIN, Texas – November 2, 2016 – The Clinical Data Interchange Standards Consortium (CDISC), Critical Path Institute (C-Path), and TransCelerate BioPharma, Inc. (TransCelerate), announce the open availability of a CDISC Therapeutic Area (TA) Standard for Kidney...... -
November 1, 2016
US Food and Drug Administration Awards Critical Path Institute Three Grants, One Contract
November 1, 2016 US Food and Drug Administration Awards Critical Path Institute Three Grants, One Contract TUCSON, Ariz., November 1, 2016—The US Food and Drug Administration (FDA) has awarded Critical Path Institute (C-Path) three grants to develop data standards, as well as a contract to continue its research into drug-induced kidney injury. With these awards, the FDA...... -
October 31, 2016
Critical Path Institute and CHDI Foundation, Inc., establish a consortium to expedite approval of Huntington’s disease therapeutics
Oct 31, 2016 Critical Path Institute and CHDI Foundation, Inc., establish a consortium to expedite approval of Huntington’s disease therapeutics TUCSON, Ariz., October 31, 2016 — Critical Path Institute (C-Path) and CHDI Foundation, Inc., are collaborating to set up a broad-based consortium that will more clearly define regulatory pathways leading to the approval......